A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Conditions: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Interventions: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsors: Chongqing University Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Rectal Cancers | Research | Skin Cancer | Squamous Cell Carcinoma | Study | Xeloda